Key result
Vincristine stimulates rat megakaryocytopoiesis, an effect blocked by normal but not vincristine-treated platelets.
Why the study?
Appropriate low dosages of vincristine stimulate megakaryocytopoiesis and produce thrombocytosis, but the mechanism involving platelets is unclear.
Answers are grounded in this paper and cite their sources.
Experimental study demonstrates that low-dose vincristine drives megakaryocytopoiesis in rats by altering circulating platelets, suggesting platelet-mediated feedback controls thrombopoiesis.
Appropriate low dosages of vincristine stimulate megakaryocytopoiesis and produce thrombocytosis. In this study of the thrombocytotic action of vincristine, administration of a single dose of 0.1 mg/kg to rats produced an increase in megakaryocyte concentration, diameter and 24 h [3H]thymidine labelling index. Transfusion of one body equivalent of platelets from normal donors prevented stimulation of megakaryocytopoiesis by vincristine whereas platelets from vincristine-treated donors did not. These results suggest that vincristine stimulates megakaryocytopoiesis by altering the functional role of circulating platelets in the regulation of thrombopoiesis.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (1977) studied this question. Vincristine vs. Normal donor platelets was evaluated on Megakaryocyte concentration, diameter and 24 h [3H]thymidine labelling index. Administration of a single /kg dose of vincristine to rats stimulated megakaryocytopoiesis, an effect prevented by transfusion of normal platelets but not vincristine-treated platelets.
Synapse has enriched 10 related papers. Consider them for comparative context: